A new study in the journal Diabetes Technology & Therapeutics evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its potential to reduce post-meal hyperglycemia in adults with type 1 diabetes. TI has a more rapid onset of action than rapid-acting insulin analogs.
Leave A Comment